| Hum. Mol. Genet
| [0002]
|
| Curr. Drug Target
| [0002]
|
| Proc. Natl. Acad. Sci. USA
| [0002]
|
| Kidney Int.
| [0002]
|
| J. Neurobiol.
| [0002]
[0009]
|
| CNS & Neurological Disorders-Drug Targets
| [0003]
[0009]
|
| J. Med. Chem.
| [0003]
[0009]
|
| Am. J. Pharmacogenomics
| [0004]
|
| Curr. Cardiol. Rep.
| [0004]
|
| Proc. Natl. Acad. Sci. USA
| [0004]
|
| J. Neurosci.
| [0004]
|
| Proc. Natl. Acad. Sci. USA
| [0005]
|
| Proc Natl. Acad. Sci. USA
| [0006]
|
| Drug Discovery Today
| [0007]
|
| Annu. Rev. Pharmacol. Toxicol.
| [0007]
|
| J. Med. Chem.
| [0007]
|
| Trends Pharmacol. Sci.
| [0007]
|
| J. Pharmacol. Exp. Ther.
| [0008]
|
| British J. Pharmacol.
| [0008]
|
| TRENDS in Pharmacological Sciences
| [0009]
|
| Current Opinion in Neurobiology
| [0009]
|
| J. Clin. Invest.
| [0009]
|
| Trends Pharmacol. Sci.
| [0009]
|
| Am. J. Otol.
| [0009]
|
| Hear. Res.
| [0009]
|
| Tip.
| [0009]
|
| Clin. Otolaryngol.
| [0009]
|
| Laryngol. Otol.
| [0009]
|
| Design of Prodrugs
| [0179]
|
| Drug and Enzyme Targeting, Part A
| [0179]
|
| Design and Application of Prodrugs
| [0179]
|
| Adv. Drug Delivery Revs.
| [0179]
|
| J. Pharmaceut. Sci.
| [0179]
|
| Chem. Pharm. Bull.
| [0179]
|
| Labeled Compounds (Part A)
| [0181]
|
| J. Pharmaceut. Sci.
| [0193]
|
| AAPS Pharm. Sci. Tech
| [0193]
|
| Chem. Commun.
| [0193]
|
| Nature Biotechnology
| [0198]
|
| Inflammatory Pain
| [0199]
|
| J. Neurosci.
| [0210]
|
| Br. J. Pharmacol.
| [0211]
|
| Proc. Soc. Exp. Biol. Med.
| [0213]
|
| J. Biol. Chem.
| [0214]
|
| J. Biomol. Screen
| [0223]
|
| J. Neurosci. Methods
| [0245]
|
| Naunyn-Schmiedeberg's Archives of Pharmacol.
| [0247]
|
| Pain
| [0249]
|
| Pain
| [0252]
|
| Biochemistry & Behavior
| [0254]
|
| Analgesic Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout
| [0274]
|
| Analgesic, Antipyretic and Anti Inflammatory Drugs
| [0274]
|
| J. Org. Chem.
| [0380]
|